Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)

This study has been completed.
Sponsor:
Collaborators:
University of Oxford
European and Developing Countries Clinical Trials Partnership (EDCTP)
Information provided by (Responsible Party):
Aeras
ClinicalTrials.gov Identifier:
NCT01151189
First received: June 24, 2010
Last updated: July 29, 2015
Last verified: July 2015

June 24, 2010
July 29, 2015
July 2011
May 2014   (final data collection date for primary outcome measure)
Percentage of Participants With Adverse Events [ Time Frame: Adverse Events (AEs) are recorded for 28 days post vaccination, Serious Adverse Events (SAEs) for at least 6 months post second vaccination. ] [ Designated as safety issue: Yes ]
The primary objective of this study is to evaluate the safety of MVA85A/AERAS-485 compared to placebo in HIV-infected, African adult subjects without active TB disease.
The primary objective of this study is to evaluate the efficacy of MVA85A/AERAS-485 in the prevention of TB disease compared to control subjects who receive placebo in HIV-infected, African adult subjects without active TB disease. [ Time Frame: Study day 0 post-vaccination through the end of study follow-up (i.e., minimum of 24 months) ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01151189 on ClinicalTrials.gov Archive Site
  • Number of TB Cases [ Time Frame: For at least 6 months post second vaccination up to 33 months total follow-up. ] [ Designated as safety issue: No ]
    Efficacy of MVA85A/AERAS-485 in the prevention of TB disease compared to control subjects who received placebo in HIV-infected, African adult subjects without active TB disease.
  • CD4+ Lymphocyte Counts Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in Anti-retroviral Therapy Negative (ART -)Subjects [ Time Frame: Up to 6 months post second vaccination. ] [ Designated as safety issue: Yes ]
  • CD4+ Lymphocyte Counts Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in ART+ Subjects [ Time Frame: Up to 6 months post second vaccination. ] [ Designated as safety issue: Yes ]
  • HIV-1 Viral Load Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in ART - Participants [ Time Frame: Up to 6 months post second vaccination. ] [ Designated as safety issue: Yes ]
  • HIV-1 Viral Load Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in ART+ Participants. [ Time Frame: Up tp 6 months post second vaccination ] [ Designated as safety issue: Yes ]
  • Counts of Spot-forming Units After Stimulation With AG85A Peptide Pool. [ Time Frame: 28 days post second vaccination. ] [ Designated as safety issue: No ]
    Immunogenicity of MVA85A/AERAS-485 compared to placebo as described by the ex vivo interferon (IFN)-γ enzyme linked immunospot (ELISpot).
  • Immunogenicity of MVA85A/AERAS-485 Compared to Placebo as Described by Flow Cytometric Intracellular Cytokine Staining (ICS) of CD4+ and CD8+ T Cells After Stimulation With a Peptide Pool of Mycobacterial Antigens. [ Time Frame: 7 days post second vaccination. ] [ Designated as safety issue: No ]
    The antigen-specific negative control-subtracted response for any cytokine (Interferon gamma [INFγ] , Interleukin 2 [IL2], Interleukin 17 [IL17] and tumor necrosis factor [TNF]).
  • QuantiFERON (QFN) Conversion Rate in MVA85A/AERAS-485 Recipients Compared to Control Subjects Without a Diagnosis of Tuberculosis During the Trial. [ Time Frame: For at least 6 months post second vaccination up to 33 months total follow-up. ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)
A Phase II, Proof of Concept, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Protective Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in Healthy, HIV-infected Adults

This is a phase II, proof of concept, randomized, double-blind, placebo-controlled study to evaluate the protective efficacy against TB disease, safety, and immunogenicity of MVA85A/AERAS-485 in healthy, HIV-infected adults.

This study consists of 650 adults subjects (ages 18-50 years of age inclusive) who will receive study vaccine or placebo at Study Day 0 and again 6-9 months later. Samples for real-time evaluation of immunogenicity were to be collected from 70 subjects (immunogenicity analysis set).

This Phase II multi-country trial was conducted as a randomized, double-blind, placebo-controlled trial in 650 HIV-positive adults with no evidence of active TB disease. Subjects were stratified at the time of randomization by whether or not they were receiving anti-retroviral therapy (ART) and then randomized in a ratio of 1:1 to receive either MVA85A/AERAS-485 at 1 x 10^8 plaque forming units (pfu) or placebo (Candin). Randomization of each group was capped so that at least 50% of the subjects randomized were receiving ART at randomization. Subjects were to receive an intradermal injection of MVA85A/AERAS-485 or placebo on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485 or placebo. The minimum follow-up period for each subject was 6 months after their last vaccination, during which subjects were followed for safety, clinical signs and symptoms of TB, and immunogenicity. All subjects were to continue to be followed every 3 months until the last subject enrolled had been followed for 6 months after their last vaccination.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Tuberculosis
  • HIV Infections
  • Biological: MVA85A/AERAS-485
    Subjects received intradermal injection of MVA85A/AERAS-485 on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485.
    Other Name: MVA85A/AERAS-485
  • Biological: Placebo
    Subjects received an intradermal injection placebo on Study Day 0, followed 6-9 months later by a booster injection of placebo.
    Other Names:
    • Candida albicans Skin Test Antigen
    • Candin
  • Placebo Comparator: Placebo
    The placebo is a licensed product manufactured by Allermed, Inc. and is used for evaluation of delayed-type of hypersensitivity reactions in adults.
    Intervention: Biological: Placebo
  • Experimental: MVA85A/AERAS-485
    MVA85A/AERAS-485 is a recombinant modified vaccinia virus Ankara expressing the M. tuberculosis antigen, Ag85A. Dosage of the study vaccine to be administered will be 1x10^8 pfu.
    Intervention: Biological: MVA85A/AERAS-485
Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dièye S, Dieye TN, Esmail H, Goliath R, Huygen K, January V, Ndiaye I, Oni T, Raine M, Romano M, Satti I, Sutton S, Thiam A, Wilkinson KA, Mboup S, Wilkinson RJ, McShane H; MVA85A 030 trial investigators. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2015 Mar;3(3):190-200. doi: 10.1016/S2213-2600(15)00037-5. Epub 2015 Feb 26.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
650
September 2014
May 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Has completed the written informed consent process prior to undergoing any screening evaluations.
  • Either males or females aged 18-50 years (inclusive) on Study Day 0
  • In general good health, confirmed by medical history and physical examination
  • Has ability to complete follow-up period as required by the protocol
  • Has laboratory evidence of human immunodeficiency virus (HIV) infection, defined as a positive HIV-1 ELISA test plus a positive confirmatory test (e.g., a second HIV-1 ELISA, polymerase chain reaction (PCR), or rapid ELISA) diagnosed prior to randomization
  • Is willing to allow the investigators to discuss the subject's medical history with the subject's HIV physician
  • Has 2 CD4+ lymphocyte count test results >350 cells/mm3, performed at least 4 weeks apart, one performed within 6 months prior to randomization and one within 30 days prior to randomization
  • Has either: a) a negative QuantiFERON-TB Gold In-Tube test result and tuberculin purified protein derivative (PPD) skin test ≤5 mm induration within 30 days prior to randomization or; b) a positive QuantiFERON-TB Gold In-Tube test result and/or tuberculin PPD skin test >5 mm and has completed 6 months of isoniazid preventive therapy prior to randomization or; c) a positive QuantiFERON-TB Gold In-Tube test result and/or tuberculin PPD skin test >5 mm and has completed treatment for TB disease within 3 year prior to randomization
  • Females: Ability to avoid pregnancy during the trial. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must avoid pregnancy by using an acceptable method of avoiding pregnancy from 28 days prior to administration of the study vaccine through the end of the study. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the use of a condom or a diaphragm combined with spermicide.
  • Has completed the written informed consent process for simultaneous enrollment in Aeras Vaccine Development Registry protocol

Exclusion Criteria:

  • Acute illness
  • Fever (temperature > 37.5°C)
  • Significant symptomatic infection
  • Any evidence of active tuberculosis (TB) disease, as determined by any clinical, radiological, or microbiology measurements.
  • Any AIDS defining illness by WHO criteria
  • Has received antiretroviral therapy (ART) in the two months prior to study entry (women who have received ART as part of the Prevention of Mother-to-Child Transmission [PMTCT] program and completed this more than 2 months prior to randomization ARE eligible)
  • Use of any investigational or non-registered drug, vaccine or medical device other than the study vaccine within 182 days preceding dosing of study vaccine, or planned use during the study period
  • Previous receipt of a recombinant modified vaccinia Ankara (MVA) or fusion protein (FP) vector at any time.
  • Is enrolled in any other clinical product trial
  • Administration of methotrexate, azathioprine, cyclophosphamide, oral corticosteroids (for corticosteroids, this will mean prednisolone, or equivalent, ≥0.5 mg/kg/day; inhaled and topical steroids are allowed) and other immunosuppressive therapies, or blood products or blood derivatives within the six months prior to randomization
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products
  • Presence of any history of cancer [except basal cell carcinoma of the skin and cervical carcinoma in situ], or renal failure
  • Evidence of severe depression, schizophrenia or mania
  • Pregnant females and females who are breast-feeding
  • Any history of anaphylaxis in reaction to vaccination
  • Principal investigator assessment of lack of willingness to participate and comply with the protocol, or increase in the participant's risk of adverse outcome
Both
18 Years to 50 Years
No
Contact information is only displayed when the study is recruiting subjects
Senegal,   South Africa
 
NCT01151189
C-030-485
Yes
Aeras
Aeras
  • University of Oxford
  • European and Developing Countries Clinical Trials Partnership (EDCTP)
Principal Investigator: Souleymane Mboup Hopital Aristide Le Dantec
Principal Investigator: Robert Wilkinson University of Cape Town
Study Director: Bernard Landry Aeras
Aeras
July 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP